6,678 trials
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Percent Coefficient of Fat Absorption (CFA) — 78.27; 80.35 percent CFA — p=0.4590
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 After 12 Weeks on Study Drug — 0.0378; 0.0947 Litre — p=0.3025
Schizophrenia, Undifferentiated Type
Primary: Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) — -0.25; -0.21; 3.8; 0.2 arbitrary units of activation
Menstrual Migraine
Primary: Migraine Recurrence — 0; 2 participants
Attention-deficit/Hyperactivity Disorder
Primary: Conners Adult ADHD Rating Scale - Short Version (CAARS) — 50.59; 46.86; 47.32; 45.36 T score — p=<0.001
Attention Deficit Disorder With Hyperactivity
Primary: Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2 — 1.7; 1.4; 1.3; -0.4 Units on a scale
Traumatic Brain Injury · Subarachnoid Hemorrhage
Primary: Seizure Incidence — 5; 3 Participants
Detrusor Overactivity · Overactive Bladder
Primary: Change From Baseline to Week 12 in Bladder Wall Thickness — 0.00; -0.29; -0.18; -0.24 mm — p=0.095
Advanced Idiopathic Parkinson's Disease
Primary: Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit — 58; 26; 3; 0 participants
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
Retraction of Colostomy
Primary: Total Opioid Burden — 112.38; 19.8 mg morphine equivalent
Glaucoma
Primary: Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8 — -3.60 milllimeters mercury (mmHg)
Obesity
Primary: Weight Loss — 2.0 percentage of weight
Periodontal Disease
Primary: Pharmacokinetics — 89.9; 41.8; 3.72; 5.13 ng/mL
Major Depressive Disorder
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8 — -11.0; -16.1 Units on a scale — p=<0.00001